N/A
N=102
Videos for Advance Care Planning in Young Adults
Advanced Cancer
Bottom Line
View on ClinicalTrials.gov: NCT04149704 ↗Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: Increased Concordance Rate in Stated Goals of Care (Life-prolonging Medical Care, Selective Medical Care, or Comfort-focused Care) — 20; 15; 5; 10 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- ACP video decision aid (Behavioral); Usual Care- (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Dana-Farber Cancer Institute
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Increased Concordance Rate in Stated Goals of Care (Life-prolonging Medical Care, Selective Medical Care, or Comfort-focused Care) |
20; 15; 5; 10; 13; 15 | — |
| SECONDARY Increased Advance Care Planning (ACP) Conversations |
13; 13; 2; 4 | — |
Summary
This study is a randomized trial of adolescent and young adults with advanced cancer and their caregivers to assess preferences for care in advanced cancer. This research study is examining the similarities and differences between patient's and caregiver's goals of cancer care.
The names of the study interventions involved in this study may include:
* Questionnaires
* Video
* Phone Interview
Eligibility Criteria
All patients will be recruited from the outpatient clinics of Dana-Farber Cancer Institute (both pediatric and adult clinics),the inpatient settings of Boston Children's Hospital and Brigham and Women's Hospital, the inpatient or outpatient clinics of Massachusetts General Hospital, or virtually. Eligible study participants will give written consent to the primary investigator or study staff member before initiation of study procedures if recruited in-person. If participants are enrolled and complete study procedures virtually, they will provide verbal consent before initiating study procedures.
If in-person visits cannot be conducted, eligible participants will be still be mailed a pre-notice letter that offers the chance for participants to opt-out or opt-in via email or phone call. After one week, we will call participants we have not heard from and ask if they would consider participating.
Patient Eligibility criteria will include patients who are:
i) Diagnosed with advanced cancer (i.e., initial first-line therapy is unsuccessful, marked by progression or relapsed disease) ii) Aged between 18-39, which is the legal age for completing an ACP document (e.g., POLST/MOLST); iii) Speak English; and iv) Have a caregiver or identified surrogate decision maker who is able to participate.
v) Treated at Dana-Farber Cancer Institute or Massachusetts General Hospital
Exclusion criteria will include:
i) A diagnosis of low-grade glioma given the fact that progressive or relapsed low grade may not be clinically characterized as advanced disease and associated poor prognosis.
ii) Visually impaired (note, hearing impaired is not an exclusion as the video is closed captioned); iii) Psychological state not appropriate for ACP discussions as determined by the primary oncologist; and, iv) Unable to participate in ACP discussions due to mental incapacity as determined by the Short Portable Mental Status Questionnaire
Data sourced from ClinicalTrials.gov (NCT04149704). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.